Patient Guide to Support Services



IncyteCARES (Connecting to Access, Reimbursement, Education, and Support) provides a single point of contact through a registered nurse to assist eligible patients and healthcare providers in obtaining access to Jakafi (ruxolitinib) and to connect them with continuing support and resources.

Jakafi, a kinase inhibitor, is indicated for the treatment of patients with intermediate- or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis, and post-essential thrombocythemia myelofibrosis. Jakafi is also indicated for the treatment of patients with polycythemia vera who have had an inadequate response to or are intolerant of hydroxyurea (Table).

IncyteCARES Services

IncyteCARES provides several services for patients who are using Jakafi, including:

  • Reimbursement support, including insurance benefit verification, information about prior authorizations, and guidance with appealing insurance denials or coverage restrictions
  • Financial assistance options, including copay/coinsurance assistance, free medication program, temporary access for insurance coverage delays, and referrals to independent nonprofit organizations and foundations
  • Education and support, including access to registered nurses, educational information about your condition and Jakafi, and a patient welcome kit
  • Connection to support services, including referrals for transportation assistance, and access to patient advocacy organizations for counseling and emotional support resources.

Financial Support

The IncyteCARES program assists patients across all patient insurance types. Patients without prescription drug coverage for Jakafi, or those whose insurance has denied claims for Jakafi treatment, may be eligible to receive the drug free of charge through the IncyteCARES Patient Assistance Program.

For patients with commercial or with private insurance, the IncyteCARES Copay/Coinsurance Assistance Program offers copay or co­insurance assistance that may help eligible patients pay as little as $25 a month for Jakafi.

Patients with government health insurance programs (eg, Medicare) who are underinsured may receive referrals to independent foundations that offer financial support.

Eligible patients experiencing an insurance coverage delay can receive a free supply of Jakafi.


IncyteCARES Patient Assistance Program

To enroll in the IncyteCARES Patient Assistance Program, patients must:

  • Reside in the United States or Puerto Rico
  • Have an annual household income of <$125,000 or 600% of the federal poverty level, whichever is greater
  • Have a valid prescription for Jakafi for an FDA-approved indication.

IncyteCARES Copay/Coinsurance Assistance Program

Patients eligible for Jakafi pay as little as $25 monthly. The amount of savings for Jakafi will not exceed $11,977 monthly and $25,000 annually.

Patients may qualify for enrollment in the program if they:

  • Reside in the United States or Puerto Rico
  • Have a valid prescription for Jakafi for an FDA-approved indication
  • Have a commercial or private ­insurance
  • Are not covered under Medicare, Medicaid, or TriCARE.

Referrals to Foundations

For patients who are not eligible for other forms of assistance or who have Medicare Part D and cannot afford Jakafi, IncyteCARES may refer them to independent, nonprofit organizations and copayment assistance foundations.

To apply, patients should create an informative list consisting of their medical conditions and treatments, their doctor’s contact information, copay amount, household income, and information about their healthcare plan(s).

Patients who are not accepted by one foundation may be referred by IncyteCARES to another organization.

Application & Enrollment

IncyteCARES Patient Assistance Program

Patients and their providers must complete the enrollment forms and fax them to 855-525-7207 or mail them directly to the address listed on the form.

Enrollment in IncyteCARES is annual; to renew, a new enrollment form must be submitted every year. IncyteCARES will then determine prescription drug coverage and screen the patient’s need for financial assistance.

IncyteCARES Copay/Coinsurance Assistance Program

To enroll in this program, patients must call IncyteCARES (855-452-5234) to determine eligibility; a membership number is provided immediately and a copay/coinsurance card is activated for eligible patients.

To receive copay assistance, patients must contact the specialty pharmacy and provide copay information so that they can apply the copay amount toward the prescription.

IncyteCARES will verify the enrolled patient’s prescription drug coverage and coordinate with a specialty pharmacy to fill the prescription. The specialty pharmacy will then contact the patient to arrange delivery.

Table Incyte Oncology Drug

Patient support programs

Jakafi (ruxolitinib)
Intermediate- or high-risk myelofibrosis; polycythemia vera in patients who inadequately respond to or are intolerant of hydroxyurea

Subscribe to
Oncology Practice Management

Stay up to date with oncology news & updates by subscribing to recieve the free OPM print publications or weekly e‑Newsletter.

I'd like to recieve: